This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
What’s more, with many key biologics scheduled to lose patent protection in this decade, Indian pharmaceuticalcompanies ought to seize this opportunity and leverage innovative technologies to introduce quality and way more affordable biosimilars in the domestic as well as global markets.
“There’s a lot that drugdevelopment for more common diseases could learn from rare disease R&D”. I think there’s a lot that drugdevelopment for more common diseases could learn from rare disease R&D.”. We have to be innovative to get around those challenges. Rare diseases during COVID. About the author.
RSV researchers at major pharmaceuticalcompanies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceuticalcompanies are pushing to developdrugs and vaccines for RSV with these populations in mind.
The company expects to commence P-I clinical trials on metastatic and pediatric primary bone cancer patients. Other radiotherapies under the company's pipeline include Humalutin and Alpha37. Nordic is advancing the development of CD37-targeted therapies for hematological cancers and immune diseases.
But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.
Several drugdevelopment trends are driving injectables demand. This includes the rising number of biologic drugs on the market, which are mostly administered parenterally. FirstLine was developed with a zero-defect philosophy,” explains Santambrogio. This was higher than the number of approvals in 2019 and 2020.
After the outbreak of any epidemic or pandemic, all the responsibilities come on the shoulders of pharmaceuticalcompanies. With unprecedented diseases lurking on the corner, pharmaceuticalcompanies, are now obligated to widen their conventional horizons and look for substitute practices in their drugdevelopment strategies.
It was once derided as the stuff of science fiction, but in recent years, biotechnology has emerged as an important growth area in pharmaceuticals. As understanding of biological systems has forged ahead, pharmaceuticalcompanies have made increasing use of biotechnology in discovering and manufacturing new medicines.
Slaoui rose through the ranks at the big UK pharma and was appointed head of the company’s vaccines division in 2009, leaving in 2017 when Emma Walmsley took over as CEO at GSK. The post Mega biotech Centessa beams up ex-Warp Speed science chief Slaoui appeared first on.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content